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Abstract
Introduction Major depressive disorder is one of the most
disabling and common diagnoses amongst psychiatric
disorders, with a current worldwide prevalence of 5–10%
of the general population and up to 20–25% for the lifetime
period.
Historical perspective Nowadays, conventional treatment
includes psychotherapy and pharmacotherapy; however,
more than 60% of the treated patients respond unsatisfac-
torily, and almost one fifth becomes refractory to these
therapies at long-term follow-up.
Nonpharmacological techniques Growing social incapacity
and economic burdens make the medical community strive
for better therapies, with fewer complications. Various
nonpharmacological techniques like electroconvulsive ther-
apy, vagus nerve stimulation, transcranial magnetic stimu-
lation, lesion surgery, and deep brain stimulation have been
developed for this purpose.
Discussion We reviewed the literature from the beginning
of the twentieth century until July 2009 and described the
early clinical effects and main reported complications of
these methods.
Keywords Major depressive disorder . Electroconvulsive
therapy . Vagus nerve stimulation . Transcranial magnetic
stimulation . Psychosurgery . Deep brain stimulation
Introduction
Major depressive disorder (MDD) is one of the most
disabling and common diagnoses throughout psychiatric
disorders. It represents a current prevalence of 5% to 10%
of the general population according to worldwide large-
scale studies, and up to 20% to 25% for the lifetime period
[98, 122]. Conventional treatment includes psychotherapy
and a wide number of antidepressant drugs; however,
over 60% of treated patients responds unsatisfactorily,
and almost one fifth becomes refractory to these treat-
ments at long-term follow-up [1, 31, 69, 86, 91]. Therapy
failure can lead to a life-threatening situation illustrated by
the high number of suicides occurring in up to 15% of
individuals [1]. In an attempt to find solutions for this
intractable disorder, other more invasive methods have been
developed.
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Search strategy
All articles and textbooks containing nonpharmacological
treatments for MDD, with the exception of psychothera-
peutic therapies, were reviewed. The reports were found via
Medline search (PubMed) using the following keywords
and their combinations: MDD, depression, electroconvul-
sive therapy (ECT), vagus nerve stimulation (VNS), trans-
cranial magnetic stimulation (TMS), psychosurgery, and
deep brain stimulation (DBS). In total, 252 reports and
eight textbooks were found describing the use of nondrug-
related and nonpsychotherapeutic treatments for depression.
Finally, 109 reports were selected for this review; the rest of
the articles were excluded due to data repetition or absence
of clinical outcome information.
Ablative surgery included lobotomy/leucotomy, orbital
and cortical undercutting, cingulectomy (cingulotomy),
subcaudate tractotomy, and limbic leucotomy (subcaudate
tractotomy with anterior cingulotomy) [17, 18, 55, 62, 78,
104, 120]. Targets for DBS included the subgenual
cingulate cortex (Brodmann area 25), nucleus accumbens,
ventral caudate/striatum, inferior thalamic peduncle, globus
pallidus internus, and the lateral habenula [5, 51, 64, 72, 73,
100, 101]. In this review, we present the early clinical
outcome and complications of these different methods.
Historical perspective
Depression is a nosologic entity that has afflicted human-
kind throughout its existence. The first description of a
depressive state was made at the era of Hellenic enlighten-
ment by Hippocrates, derived from one of the four humors,
the melancholia. In ancient times, brain surgery was
performed to treat mental problems in order to exorcise or
appease spirits and ghosts. In 1888, the psychiatrist Gottlieb
Burkhardt performed one of the first psychosurgical
interventions through cortical excisions with the intention
to treat a diagnosed mental illness, schizophrenia in that
case. Even though the majority of his patients improved,
one of them died, and many others presented serious
complications due to the procedure [110]. Consequently, his
results were interpreted as careless and unreliable, leaving
place to almost 50 years without any related attempt to treat
the medically refractory cases. It was not until 1936 that
António Egas Moniz, in collaboration with Almeida Lima,
brought in modern psychosurgery with apparent better
results; these contributions to science led Moniz to receive
the Nobel Prize in 1949 [78]. Together, they developed the
technique of prefrontal leucotomy to treat severe mental
disorders, based on previous studies in primates performed
by Fulton and Jacobsen, where frontal lobes were com-
pletely removed in two chimpanzees [39]. A few years
later, Walter Freeman and James Watts performed loboto-
mies on numerous cases and popularized this procedure.
They even introduced a novel orbital approach with the use
of the so-called ice-pick leucotome [37, 38, 118]. Until the
1950s, thousands of lobotomies were carried out around the
globe, but the first discordances started to come out when
scientific evidence showed no evident benefit of the surgery
and, in some cases, even worsening of symptoms. In
parallel, ECT was developed and was considered to be a
revolutionary technique indicated for acute episodes of
severe depression [12]. However, the broad clinical
introduction of antipsychotics and antidepressants in the
sixties led to a vast decrease in the use of surgical and
electroconvulsive procedures for some decades, until the
end of the past century.
In recent years, increased interest in psychiatric disorders
and the introduction of worldwide accepted, standardized
clinical guidelines have made it possible to perform an
accurate diagnosis of the illness. Ethical committees have
led to stricter diagnostic criteria and a more scientific
approach of epidemiological studies. In recent history,
newer techniques have also been developed; in the last
decades, the novel interventions such as VNS, TMS, and
DBS have been added as treating options for MDD. The
surgical techniques have become more precise, safer, and
more importantly nonlesional.
Electroconvulsive therapy
ECT was introduced in the late 1930s and was very rapidly
accepted because of its effectiveness in severe psychiatric
disorders. After years of animal experiments by Lucio Bini
and Ugo Cerletti, the first patient was successfully treated
in 1938 with constant alternant current electrical pulses
over 200 V [12, 13, 19, 28]. Even though ECT was
originally introduced for schizophrenia solely, this tech-
nique was widely used for almost all mental illnesses after a
short period of time. Subsequently, when the method
gained an ample recognition, the indications, contraindica-
tions, and search for proper parameters of stimulation were
the subjects of investigation. In the 1950s, ECT and other
therapeutic options for the time were eclipsed by the arrival
of psychiatric pharmacotherapies; nonetheless, it showed its
usefulness again many years later, by being effective in
pharmacologically resistant patients [32, 82].
Nowadays, after grand stigmatization for decades, ECT
prevails as one of the most effective therapies in the
treatment of severe depressive events; it can reach an effect
of up to 80% [32]. The repetition of this therapy should
only be considered in patients who responded well to
previous acute sessions [2]. Unfortunately, the benefit is
usually not long lasting [36]. This procedure will probably
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remain a viable therapeutic option in medically resistant
patients. It should never be considered as a first treatment
alternative, which remains pharmacotherapy, due to its
costs and temporary documented side effects like confusion
and retrograde and/or anterograde amnesia [30].
Vagus nerve stimulation
VNS was first introduced as an experimental anticonvulsant
procedure in dogs by Jacob Zabara in 1985 [123, 124]. A
few years later, Kiffin Penry and Dean treated the first
human case with VNS in order to treat epilepsy [87]. After
several successful studies of epilepsy conducted in numer-
ous centers, the pioneer case with treatment-refractory
depression (TRD) as the indication for VNS was presented
by Rush et al. at the end of the 1990s [40, 95]. The
rationale was based on the beneficial effects on depressive
symptoms in patients who had previously received VNS for
seizures, but the exact mechanism of action was not known
[26, 43, 49]. Long-term studies have proven the good
clinical outcome of VNS for MDD while it is well
tolerated; a successful response have been described in half
of the patients, with complete remission in one third [40,
95, 96, 102]. Even though its mechanism of action is not
completely clarified, immunohistological (in animals) and
imaging (in TRD patients) studies have endorsed its clinical
effect [81, 85]. It is believed that once the input information
from the vagus nerve project into the solitary tract nucleus,
it follows an ascending pathway to modulate various
structures such as the amygdala, dorsal raphe, locus
coeruleus, and the ventromedial prefrontal cortex that
produces the effect over mood in patients [85].
Further research is required to elucidate the specific
action of VNS, considering the anatomy of the vagus nerve
with its projections. Moreover, cost-effectiveness studies
are still lacking. Something to keep in mind is that
immediately postoperatively and at short-term follow-up,
VNS has shown a low effectiveness [76, 102]. However, its
beneficial effect at long-term in a substantial amount of
patients, together with its low number of unwanted side
effects, make this method an attractive treatment for
patients suffering from MDD.
Transcranial magnetic stimulation
TMS is an innovative technique and highly appealing to
scientists and patients because of its noninvasive nature.
TMS directly modulates superficial areas of the brain. It has
been recently developed, and several theories about its
mechanism of action have been proposed; induction of
neurotransmitter release that alters brain physiology and
neuronal depolarization seem to be the most important
elements, but more data are required to confirm these
statements [10, 11, 84]. In recent times, animal and clinical
models have been used trying to understand the antidepres-
sant effects of TMS [33, 34, 52–54, 103]; functional
imaging has demonstrated specific changes induced by
TMS in brain metabolism, perfusion, and interconnections
[23].
High-frequency TMS of the left dorsolateral prefrontal
cortex has shown effectiveness in almost one third of
pharmacotherapy-resistant MDD patients, always with
significant differences compared with sham stimulation [6,
83]. Furthermore, differential opposite effects on depressive
behavior have been observed when low versus high
frequencies were compared [60, 108]. TMS is a safe
procedure with no apparent structural damage after usage
for several weeks; some of its advantages are its great
tolerance in all patients, the lack of cognitive deterioration,
or any other unwanted side effects. However, many
questions regarding its mechanism of action have to be
answered before expanding its use or indications. Another
limitation is the duration of the effect, reflected on a
worsening of depressive symptoms only 3 weeks after
stimulation. This could represent a serious restraint since
continuous stimulation is not possible with TMS.
Lesion procedures
Ablative surgery to treat mental illnesses is one of the
therapies that has expanded more rapidly and widely as a
nonpharmacological therapy. Throughout decades, many
targets, approaches, and techniques have been tried, with
diverse and sometimes contradictory outcomes. Although
the effects on mood gained the attention of medical
community, due to the growing prevalence and socioeco-
nomic burden, often no objective measurement of the
effects was performed, and probably misdiagnosed patients
were included into the studies.
Lobotomy/leucotomy
In 1936, the term psychosurgery was first used in Moniz'
prefrontal leucotomy publication in patients with dementia
[78]. One year later in 1937, Freeman and Watts introduced
a novel approach for the prefrontal leucotomy: the
Freeman–Watts standard lobotomy, where a 5-cm-long
leucotome was introduced through the roof of the orbit in
the direction of the sutura coronalis to perform lesions [37].
Leucotomy by that time was accepted by a great part of the
medical community as a treatment for patients with several
psychiatric disorders. Publications between 1951 and 1972
showed divergent results: improvement was reported in
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30% to 100% of patients, but frequently defined only as
great/much improvement or moderate/slight improvement
[14, 27, 57, 58, 75]. Two studies, however, showed no
improvement in the number of discharges from a clinic
between patients who underwent leucotomy and the control
group [74, 94]. In 1961, a report from the UK by Tooth and
Newton showed that from a group of more than 10,000
psychiatric patients with affective disorders, schizophrenia,
and other disorders, surgery achieved an improvement of
approximately 60%. However, there were many side effects
reported such as epilepsy, personality changes, urinary
incontinence and, especially, a mortality rate of approxi-
mately 4% [114].
Orbital and cortical undercutting
Scoville described in 1949 the supraorbital cortical under-
cutting of Brodmann areas 9 and 10, the gyrus cinguli, and
the orbital surface, based on previous animal experiments
that showed these structures play an important role in
emotions. It was believed that with this supraorbital
approach, discrete lesions could be performed without
disturbing the blood supply of surrounding areas. Scoville's
first results showed an improvement in all of his affective
psychotic patients. Another study with a small number of
patients showed an improvement of approximately 85%
[104, 105]. In 1955, Knight introduced a variation of
Scoville's intervention, the restricted orbital undercutting,
where he limited the lesion directing his dissection less
laterally. Knight based his planning on the circuit of Papez
and preferred a restricted resection with the argument that
lateral fibers at this level are not of interest for psychiatric
disorders; another argument for not going too laterally were
the observations that penetrating wounds in the posterolat-
eral lobes resulted in undesirable personality changes. The
intervention led to a clear improvement in 69% of patients
with depression and various psychiatric conditions [63]. In
both Scoville's intervention and its variant described by
Knight, the most important side effects included personality
changes, epilepsy, and urine incontinence.
Cingulectomy (cingulotomy)
The first description of cingulectomy as a treatment of
psychiatric disorders is from Le Beau in 1949. The first
cingulectomy reports performed in monkeys resulted in
unresponsiveness and placidity when Brodmann's cortical
area 24 was aspirated via a fine suction. LeBeau found no
improvement of the same treatment in five depressive
patients with anxiety and pain but good results in three out
of four patients with depression and obsessive neurosis
[66]. In 1967, Ballantine described the first stereotactic
anterior cingulotomy for psychiatric disorders including
depression, after the publication of reports by Foltz and
White, who by that time had carried out stereotactic
cingulotomies in patients with untreatable pain [9, 35].
The stereotactic neurosurgical technique was applied for the
first time in patients by Spiegel and Wycis in 1947. It was a
milestone in neurosurgery because specific deep targets
could be reached through one burr-hole by using internal
cerebral landmarks [109]. Ballantine reported an improve-
ment in 77% of operated patients with comorbid fear and
depression. Other studies showed an improvement between
44% and 92% with personality changes, epilepsy, weight
gain, and urine incontinence as the most reported side
effects [7, 16, 93, 107].
Subcaudate tractotomy
In 1964, Knight described the stereotactic subcaudate
tractotomy using radioactive Yttrium implants in order to
perform lesions anteroventral to the head of the caudate
nucleus in the substantia innominata (SI). The goal was to
interrupt the SI fibers that run from the frontal cortex and
amygdala to the hypothalamus. Preclinical studies with
monkeys had shown that stimulation of Brodmann area 13,
an area just under the SI, caused physical phenomena
inducing violent emotions. Therefore, Knight reasoned that
a lesion in the SI could influence the intensity of emotional
responses. From the initial 15 depressive patients whom he
operated on, 14 remained therapy-free after surgery [61].
Other studies showed improvement percentages of 59–
100%. The most important reported side effects were
fatigue, weight gain, and epilepsy in 1–2% of the patients
[15, 21, 41, 48, 62, 70, 90, 111].
Limbic leucotomy
In 1973, Kelly and Richardson described the stereotactic
limbic leucotomy, which consisted of an anterior cingulot-
omy in combination with a subcaudate tractotomy. Previous
studies involving both areas had shown good results when
performed separately. Experimental results had already
shown a relation between the autonomous responses and
emotions at the level of the limbic system. Intraoperative
stimulation was applied to patients in order to evoke
physiological responses, which would confirm the exact
location of the electrode in the target. Of the first 40
operated patients, five of whom with depression, four
showed mild to large improvement of depressive symp-
toms [55, 56]. Three other studies showed an improve-
ment percentage of 30–78% [57, 79, 97]. The most
common reported side effects were drowsiness, weight
gain, and memory problems, but also, epilepsy, urine
incontinence, and personality changes were described
[55–57, 79, 97].
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Other procedures
Many other areas and approaches, different from the above-
mentioned, have been applied for ablative surgery with the
intention to cure mental illnesses; however, only poor
results or severe complications were obtained. Some of
these procedures include topectomy (also called corticec-
tomy), anterior mesoloviotomy, open frontal leucotomy,
and in some cases, multiple targets in the same procedure.
The general outcome was reported at short-term follow-up
or not mentioned; however, three studies report rehabilita-
tion in 50% of patients or more. Side effects were from
moderate to severe, mainly including seizures, personality
changes, and postoperative hemorrhage [65, 88, 112, 115].
We summarize some of the most informative and
representative outcomes in Table 1.
Deep brain stimulation
Since its successful application for tremor by Benabid et al.
in 1987, DBS is applied on a large scale for movement
disorders such as Parkinson's disease, tremor, and dystonia.
For each indication, different targets and different theories
have been developed with the intention to obtain the best
clinical results. In DBS (mostly bilateral), electrodes are
implanted in specific brain regions where high-frequency
stimulation is applied. Its widely appreciated advantages
over lesions are its reversibility and adjustability by
manipulating the stimulation parameters. Apart from move-
ment disorders, the applications in the last decade have
been extended to psychiatric disorders such as Gilles de la
Tourette syndrome and obsessive-compulsive disorder
(OCD) [42, 68, 106, 117]. In a series of reports performed
by Heath et al. between 1979 and 1981, cerebellar
stimulation was applied for the treatment of various
psychiatric pathologies including intractable depression,
schizophrenia, psychiatric conditions secondary to epilepsy,
psychotic behavior, and miscellaneous psychiatric symp-
tomatology. Concerning the depressive cases, in five out of
six patients, the symptomatology decreased significantly at
maximum follow-up without medication. However, evalu-
ation of clinical data is difficult to determine due to lack of
standardized scales and absence of other updated reports
[22, 44–46]. More recently, DBS to treat MDD has
followed diverse approaches in order to alleviate depressive
symptoms.
In 2005, Mayberg et al. presented the first clinical study
of DBS in depression. The hypothesis to stimulate this area
was acquired from observations that showed hyperactivity
of the subgenual cingulate cortex (Brodmann area 25;
Cg25) in chronic depressed patients. It was thought that this
area plays a primary role in processes like learning,
memory, motivation, and reward—behaviors that change
with depression. In this novel study by Mayberg et al., six
patients were implanted and stimulated with parameters
adjusted to the apparent optimal benefit. After 6 months, in
67% of patients, a reduction of more than 50% on the
Hamilton depression rating scale (HDRS) was seen, with a
total or partial remission in three patients. Clinically,
improvement was referred as an increase in energy, interest,
psychomotor speed, and decrease of apathy and anhedonia.
In addition, imaging studies showed normalization in the
cerebral blood flow of Cg25 and other areas which appear
to be related with depression [73].
After this first study, two case reports concerning DBS
for depression in different targets were published. In the
first report, Jiménez et al. described considerable improve-
ment after DBS of the inferior thalamic peduncle in a 49-year-
old woman with a history of recurrent episodes of major
depression for over 20 years. After 24 months follow-up of
double-blinded stimulation, the score on the HDRS decreased
significantly. After a 2-month double-blinded OFF stimula-
tion period, there was an evident worsening of symptomatol-
ogy with an increase on depressive scales, suggesting that the
positive effect was obtained by DBS and not due to a placebo
effect [51]. In the second report, Kosel et al. described the
case of a 62-year-old woman with treatment refractory MDD
with comorbid neuroleptic-induced tardive dyskinesias. DBS
of the globus pallidus internus induced an evident drop in the
HDRS score after stimulation [64]. Schlaepfer et al.
published the positive results of DBS of the nucleus
accumbens for depression in three patients, with an
immediate effect on depressive ratings. Double-blinded
periods with stimulation ON and OFF demonstrated a
beneficial outcome only when ON stimulation was applied.
Moreover, the positive behavioral changes in these patients
were supported by positron emission tomography imaging
that correlated symptomatology with an augmentation of
metabolism in the nucleus accumbens, amygdala, and
dorsolateral and dorsomedial prefrontal cortex, and reduced
metabolism in the ventral and ventrolateral medial prefrontal
cortex [101]. On the other hand, Aouizerate et al. implanted
electrodes in two patients with a history of MDD and OCD.
After clinical evaluations, they concluded that the best target
for DBS to alleviate OCD symptoms was the ventral
caudate, and for the best outcome in depression, the nucleus
accumbens was pointed as the best option [3]. In a recent
study, Sartorius et al. reported on the case of a 64-year-old
woman with history of TRD for over four decades treated
with DBS in the lateral habenula. After electrode implanta-
tion, the patient presented two relapses, one attributable to
initial adjustment of parameters and the second probably due
to a traumatism. When the proper functioning of the
stimulator was demonstrated, complete remission was
achieved for several weeks. After 60 weeks of DBS, the
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Non-pharmacological treatment options in major depressive disorder 571
patient remained with an HDRS score of 0 without reported
complications or side effects [100].
Nowadays, six main DBS targets of interest remain that
have been reported (Table 2). Neuromodulation could be
one of the most efficient techniques for this disorder due to
the fluctuant behavior of patients and the high co-morbidity
that accompanies this condition. Analysis of DBS results of
the mentioned targets shows promising responses and
evident positive outcomes with minimal side effects.
Nevertheless, cost-benefit analysis and good selection of
patients are indispensable matters for a successful result.
Discussion
In this review, we have summarized the reports of non-
pharmacological therapies for the treatment of MDD,
ablative surgery being the first method essayed at the end
of the nineteenth century. Even though it was abandoned
shortly after its initiation, it was retaken on the 1930s in a
systematic manner and applied at various centers with
diverse techniques for several decades. Nowadays, these
procedures have been abandoned due to the low results
with a high complication rate, together with the develop-
ment of minimally invasive surgery. ECT merged years
after psychosurgery as an attractive option at that time to
treat many psychiatric conditions without surgical interven-
tion, and showing special aid for severe mood crises, the
latter being one of the most important indications even
today, with over 80% of improvement if correct inclusion
criteria are used. ECT remains a valid intervention even in
our days, but with specific indications due to their
limitations. Short-lasting effects of this therapy seem to be
the most important disadvantage to take into account before
its application [32, 116]. At the beginning of the twentieth
century, the first case of VNS to treat depression was
reported. This therapy has shown since then in various
reports, positive outcomes, and good rates of remission for
MDD. However, very little about its mechanism of action
has been elucidated, and further research is needed to
endorse it. During this same time, for over one decade,
TMS has been introduced into the psychiatric field, and its
therapeutic effect over depression has been examined.
Nevertheless, stimulation guidelines and interactions with
medications should be better established to avoid relapse of
symptoms. Recently, in 2005, the first report of DBS for
MDD draws the attention to this well-established method
used to treat other conditions for over 20 years. This
procedure has demonstrated during this time high rates of
remission, low number of side effects, and very few
complications related to the surgery.
Several authors have published different outcomes for all
of these methods since the first half of the twentiethTa
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century. However, in the beginning of the past century, the
deficiency of standardized disease criteria, absence of
consensus in MDD and TRD definitions, lack of diag-
nostic instruments, poor follow-up clinimetric evaluations,
and high rates of mortality led in many cases to misuse or
abuse of these techniques. The poor description of therapy
outcomes, complications, and side effects of reports
performed in the past complicates an objective evaluation
of data in our days. These premises together could have
possibly biased the results obtained formerly. The quality
of evidence reported in many articles made it very
difficult to interpret the results and hardened the data
analysis.
On the other hand, the novel developments available
nowadays are more ethically justified with better scientific
bases, minimally invasive techniques, and more objective
evaluation instruments. Innovative procedures as VNS,
TMS, and DBS allow physicians to reproduce maximal
clinical effects for sustained periods of time that could be
adapted to each patient's needs and to combine them with
pharmacotherapy [71]. Neuromodulation offers the possi-
bility to adapt parameters to avoid undesired consequences
and to obtain the maximum clinical benefit. TMS possesses
the advantage over any other therapy by being the least
invasive procedure, but still with an unspecific target of
action and outcome. ECT is the first line option for acute
events in depressive crises. VNS, although proven to be an
effective treatment, is not yet a well-established method for
MDD. Although in all these therapies the results are
promising, their mechanisms of action should be better
clarified [84]. Algorithms should be developed to extend
these treatments in the most convenient phase of the
disorder, allowing also better combination with conven-
tional therapies.
When considering the more invasive treatment options at
the present time DBS seems to offer more advantages,
fewer complications, and fewer side effects compared with
lesions. Moreover, DBS has known more years of careful
testing compared with other stimulation methods, its
application being supported by larger scientific evidence.
Nowadays, lesions should not be considered anymore
except if no other alternative is available due to the
above-mentioned complications, low rates of success, and
irreversibility.
Depression is one of the disorders with the largest co-
morbidity rate, not only related to other psychiatric
conditions but also in association with other illnesses such
as Alzheimer and Parkinson disease among others [4, 20,
25, 51, 99]. This premise is another pending aspect that
should be kept in mind if real progress is intended for the
treatment patients suffering from MDD; in the same way,
anxiety-related symptoms should often also be evaluated in
order to measure treatment effectiveness.Ta
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Future perspective
Novel stimulatory techniques are being developed using
minimal invasive techniques. In this respect, DBS seems to
be one of the most promising procedures due to its
reversibility. DBS also offers the possibility to control the
therapeutic effect by simply switching off the stimulation,
which is usually not easily possible in other treatments. The
main problem of DBS in MDD is at the moment the diversity
of potential targets, varying from the cortex to the habenula.
One way of solving this problem is to elucidate the
mechanism of action of DBS in MDD by using computa-
tional and animal models.
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